214 related articles for article (PubMed ID: 35396200)
1. Cardiovascular benefits of GLP-1RA and SGLT-2i in women with type 2 diabetes.
Mishriky BM; Cummings DM; Powell JR
Prim Care Diabetes; 2022 Jun; 16(3):471-473. PubMed ID: 35396200
[TBL] [Abstract][Full Text] [Related]
2. Do GLP-1RAs and SGLT-2is reduce cardiovascular events in women with type 2 diabetes? A systematic review and meta-analysis.
Mishriky BM; Okunrintemi V; Jain S; Sewell KA; Powell JR; Cummings DM
Diabetes Metab; 2021 Feb; 47(1):101160. PubMed ID: 32439471
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists as complementary agents that address multi-organ defects in type 2 diabetes.
Lajara R
Postgrad Med; 2019 Nov; 131(8):555-565. PubMed ID: 31580737
[TBL] [Abstract][Full Text] [Related]
4. Gender difference in cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in type 2 diabetes: A systematic review and meta-analysis of cardio-vascular outcome trials.
Singh AK; Singh R
Diabetes Metab Syndr; 2020; 14(3):181-187. PubMed ID: 32142999
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in Asians with type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials.
Singh AK; Singh R
Diabetes Metab Syndr; 2020; 14(4):715-722. PubMed ID: 32470852
[TBL] [Abstract][Full Text] [Related]
6. Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study.
Sohn M; Dietrich JW; Nauck MA; Lim S
Cardiovasc Diabetol; 2023 Jun; 22(1):153. PubMed ID: 37381019
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A systematic review and network meta-analysis.
Hussein H; Zaccardi F; Khunti K; Davies MJ; Patsko E; Dhalwani NN; Kloecker DE; Ioannidou E; Gray LJ
Diabetes Obes Metab; 2020 Jul; 22(7):1035-1046. PubMed ID: 32077218
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study.
Baviera M; Foresta A; Colacioppo P; Macaluso G; Roncaglioni MC; Tettamanti M; Fortino I; Genovese S; Caruso I; Giorgino F
Cardiovasc Diabetol; 2022 Aug; 21(1):162. PubMed ID: 35999556
[TBL] [Abstract][Full Text] [Related]
9. The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs.
Giugliano D; Longo M; Signoriello S; Maiorino MI; Solerte B; Chiodini P; Esposito K
Cardiovasc Diabetol; 2022 Mar; 21(1):42. PubMed ID: 35296336
[TBL] [Abstract][Full Text] [Related]
10. Do GLP-1RAs and SGLT-2is reduce cardiovascular events in black patients with type 2 diabetes? A systematic review and meta-analysis.
Mishriky BM; Powell JR; Wittwer JA; Chu JX; Sewell KA; Wu Q; Cummings DM
Diabetes Obes Metab; 2019 Oct; 21(10):2274-2283. PubMed ID: 31168889
[TBL] [Abstract][Full Text] [Related]
11. Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study.
Lugner M; Sattar N; Miftaraj M; Ekelund J; Franzén S; Svensson AM; Eliasson B
Cardiovasc Diabetol; 2021 Mar; 20(1):67. PubMed ID: 33752680
[TBL] [Abstract][Full Text] [Related]
12. Glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors as add-on therapy for patients with type 2 diabetes? A systematic review and meta-analysis of surrogate metabolic endpoints.
Patoulias D; Katsimardou A; Kalogirou MS; Zografou I; Toumpourleka M; Imprialos K; Stavropoulos K; Stergiou I; Papadopoulos C; Doumas M
Diabetes Metab; 2020 Sep; 46(4):272-279. PubMed ID: 32437914
[TBL] [Abstract][Full Text] [Related]
13. GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off.
Giugliano D; Scappaticcio L; Longo M; Bellastella G; Esposito K
Cardiovasc Diabetol; 2021 Oct; 20(1):205. PubMed ID: 34641876
[TBL] [Abstract][Full Text] [Related]
14. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
[TBL] [Abstract][Full Text] [Related]
15. Computing and interpreting the Number Needed to Treat for Cardiovascular Outcomes Trials : Perspective on GLP-1 RA and SGLT-2i therapies.
Ludwig L; Darmon P; Guerci B
Cardiovasc Diabetol; 2020 May; 19(1):65. PubMed ID: 32404155
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy of sodium-glucose co-transporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and non-steroidal mineralocorticoid receptor antagonists in chronic kidney disease and type 2 diabetes: A systematic review and network meta-analysis.
Nguyen BN; Nguyen L; Mital S; Bugden S; Nguyen HV
Diabetes Obes Metab; 2023 Jun; 25(6):1614-1623. PubMed ID: 36751968
[TBL] [Abstract][Full Text] [Related]
17. Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM).
Gourdy P; Darmon P; Dievart F; Halimi JM; Guerci B
Cardiovasc Diabetol; 2023 Apr; 22(1):79. PubMed ID: 37005640
[TBL] [Abstract][Full Text] [Related]
18. Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes.
Kutz A; Kim DH; Wexler DJ; Liu J; Schneeweiss S; Glynn RJ; Patorno E
Diabetes Care; 2023 Nov; 46(11):2004-2014. PubMed ID: 37677118
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes: a systematic review and network meta-analysis study protocol.
Hussein H; Zaccardi F; Dhalwani NN; Davies MJ; Khunti K; Gray LJ
BMJ Open; 2018 Nov; 8(11):e023206. PubMed ID: 30413509
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
Li CX; Liang S; Gao L; Liu H
PLoS One; 2021; 16(2):e0244689. PubMed ID: 33606705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
